Aiforia Technologies
3.94 EUR +2.34%1,148 investors are following this company
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.
P/E (24e)
-9.01
EV/EBIT (adj.) (24e)
-9.49
P/B (24e)
16.3
Dividend yield-% (24e)
-
Target price
4.20 EUR
Recommendation
Accumulate
Updated
8.3.2024
First North Finland
AIFORIA
Daily low / high price
3.85 / 3.95
EUR
Market cap
102.44M EUR
Turnover
15.69K EUR
Volume
4K
Risk and recommendation
HighRiskLow
SellRecommendationBuy
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Luiro
Head of Nordic ER Development, Analyst
Frans-Mikael Rostedt
Analyst
Latest videos
Financial calendar
Interim report
2024-08-29
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sto-Rahoitus Oy | 5.8 % | 5.8 % |
Johan Lundin | 4.9 % | 4.9 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Johan Lundin | 2023-06-22 | 495,750EUR |
Jukka Tapaninen | 2022-12-30 | 4,044EUR |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.8 | 1.0 | 1.6 | 2.4 | 4.3 | 8.1 | 14.2 | 26.2 |
growth-% | 32.9 % | 14.7 % | 64.9 % | 49.3 % | 80.1 % | 88.4 % | 75.1 % | 84.1 % |
EBITDA | -1.6 | -3.5 | -9.5 | -9.7 | -6.8 | -4.4 | -0.5 | 7.6 |
EBIT (adj.) | -2.6 | -4.7 | -11.8 | -12.9 | -11.4 | -10.2 | -6.9 | 0.8 |
EBIT | -2.6 | -4.7 | -11.8 | -12.9 | -11.4 | -10.2 | -6.9 | 0.8 |
Profit before taxes | -2.8 | -7.6 | -12.2 | -12.9 | -11.5 | -10.5 | -7.2 | 0.5 |
Net income | -2.8 | -7.6 | -12.2 | -12.9 | -11.5 | -10.5 | -7.2 | 0.5 |
EPS (adj.) | -0.14 | -0.29 | -0.47 | -0.50 | -0.44 | -0.39 | -0.26 | 0.02 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -189.8 % | -354.2 % | -593.3 % | -404.5 % | -157.8 % | -54.7 % | -3.2 % | 28.8 % |
EBIT-% (adj.) | -310.1 % | -481.4 % | -731.9 % | -537.1 % | -263.0 % | -125.4 % | -48.6 % | 3.0 % |
EBIT-% | -310.1 % | -481.4 % | -731.9 % | -537.1 % | -263.0 % | -125.4 % | -48.6 % | 3.0 % |
ROE | -386.3 % | -39.0 % | -36.2 % | -54.8 % | -95.0 % | -934.9 % | 93.4 % | -4.3 % |
ROI | -77.0 % | -20.9 % | -31.8 % | -45.4 % | -56.6 % | -60.3 % | -40.7 % | 4.8 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 5.22 | 3.23 | 3.49 | 3.94 | 3.94 | 3.94 | 3.94 | |
Shares | 20.0 | 25.8 | 25.8 | 26.0 | 26.4 | 27.2 | 27.5 | 27.5 |
Market cap | 134.6 | 83.4 | 90.6 | 103.9 | 107.3 | 108.2 | 108.3 | |
Enterprise value | 99.4 | 62.4 | 82.4 | 107.7 | 120.9 | 128.1 | 127.2 | |
EV/S | - | 102.0 | 38.9 | 34.4 | 24.9 | 14.9 | 9.0 | 4.9 |
EV/EBITDA | - | - | - | - | - | - | - | 16.8 |
EV/EBIT (adj.) | - | - | - | - | - | - | - | 164.3 |
EV/EBIT | - | - | - | - | - | - | - | 164.3 |
P/E (adj.) | - | - | - | - | - | - | - | 228.3 |
P/E | - | - | - | - | - | - | - | 228.3 |
P/B | - | 3.5 | 2.8 | 5.1 | 16.3 | - | - | - |
P/S | - | 138.2 | 51.9 | 37.8 | 24.1 | 13.2 | 7.6 | 4.1 |
Dividend yield | ||||||||
Equity ratio | 16.8 % | 86.4 % | 80.3 % | 63.5 % | 29.4 % | -17.2 % | -46.3 % | -40.4 % |
Gearing ratio | 146.0 % | -92.8 % | -71.6 % | -45.4 % | 60.6 % | -329.2 % | -175.2 % | -173.9 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 1.0 | 1.4 | 2.4 | 2.0 | 2.3 | ||||
EBITDA | -5.0 | -4.7 | -9.7 | -3.5 | -3.4 | ||||
EBIT | -6.4 | -6.5 | -12.9 | -5.5 | -5.8 | ||||
Profit before taxes | -6.5 | -6.4 | -12.9 | -5.6 | -5.9 | ||||
Net income | -6.5 | -6.4 | -12.9 | -5.6 | -5.9 |
ShowingAll content types
A reasonably significant new contract for Aiforia in the veterinary sector
Aiforia signs a contract with a veterinary health company in the US
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools